Therapies for advanced cancerspose a special challenge for health technology assessment organizations in many countries

Health Affairs, 04/13/2012

In the United States, although no separate evaluation pathways exist for cancer, cancer drugs receive special status by virtue of unique Medicare rules covering off–label indications. Worldwide, authors demonstrate that health technology assessment organizations are struggling with cancer’s “exceptionalism.”

Print Article Summary